Характеристика фенотипических особенностей нокаутных мышей с направленной инактивацией генов семейства синуклеинов

Список литературы

1. Ababou A., Ladbury J.E. Survey of the year 2005: literature on applications of isothermal titration calorimetry// J Mol Recognit. 2007. V. 20(1). P. 4−14.
2. Adamczyk A., Solecka J., Strosznajder J.B. Expression of alpha-synuclein in different brain parts of adult and aged rats// J Physiol Pharmacol. 2005. V. 56(1). P. 29−37.
3. Ahn M., Kim S., Kang M., Ryu Y., Kim T.D. Chaperone-like activities of alpha-synuclein: alpha-synuclein assists enzyme activities of esterases// Biochem Biophys Res Commun. 2006. V. 346(4). P. 1142−9.
4. Alves Da Costa C., Paitel E., Vincent В., Checler F. Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson’s disease// J Biol Chem. 2002. V. 277(52). P. 50 980−4.
5. Amrein I., Lipp H.P. Adult hippocampal neurogenesis of mammals: evolution and life history// Biol Lett. 2009. V. 5(1). P. 141−4.
6. Ansorge M.S., Zhou M., Lira A., Hen R., Gingrich J.A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice// Science. 2004. V. 306(5697). P. 879−81.
7. Baptista M.J., O’Farrell C., Daya S., Ahmad R., Miller D.W., Hardy J.,
8. Farrer M.J., Cookson M.R. Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines// JNeurochem. 2003. V. 85(4). P. 957−68.
9. Barbiroli B., Martinelli P., Patuelli A., Lodi R., Iotti S., Cortelli P., Montagna P. Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson’s disease// Mov Disord. 1999. V. 14(3). P. 430−5.
10. Barnham K.J., Bush A.I. Metals in Alzheimer’s and Parkinson’s diseases// Curr Opin Chem Biol. 2008. V. 12(2). P. 222−8.
11. Bartzokis G., Beckson M., Ling W. Clinical and MRI evaluation of psychostimulant neurotoxicity//NIDA Res Monogr. 1996. V. 163. P. 300−17.
12. Bauer L.O. Psychomotor and electroencephalographic sequelae of cocaine dependence//NIDA Res Monogr. 1996. V. 163. P. 66−93.
13. Beal M.F. Commentary on «Alpha-synuclein and mitochondria: a tangled skein"// Exp Neurol. 2004. V. 186(2). P. 109−11.
14. Bellani S., Sousa V.L., Ronzitti G., Valtorta F., Meldolesi J., Chieregatti E. The regulation of synaptic function by alpha-synuclein// Commun Integr Biol. 2010. V. 3(2). P. 106−9.
15. Benarroch E.E., Schmeichel A.M., Sandroni P., Parisi J.E., Low P.A. Rostral raphe involvement in Lewy body dementia and multiple system atrophy// Acta Neuropathol. 2007. V. 114(3). P. 213−20.
16. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V.,
17. Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease//Nat Neurosci. 2000. V. 3(12). P. 1301−6.
18. Beyer K., Ariza A. Protein aggregation mechanisms in synucleinopathies: commonalities and differences// J Neuropathol Exp Neurol. 2007. V. 66(11). P. 965−74.
19. Beyer K., Munoz-Marmol A.M., Sanz C., Marginet-Flinch R., Ferrer I., Ariza A. New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases// Neurogenetics. 2011.
20. Biala G. Behavioral and pharmacological characteristics of mice lacking the dopamine transporter.// Postepy Hig Med Dosw (Online). 2004. V. 58. P. 560−4.
21. Blumenfeld-Katzir T., Pasternak O., Dagan M., Assaf Y. Diffusion MRI of structural brain plasticity induced by a learning and memory task// PLoS One. 2011. V. 6(6). P. e20678.
22. Bohnen N.I., Muller M.L., Kotagal V., Koeppe R.A., Kilbourn M.A., Albin R.L., Frey K.A. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease// Brain. 2010. V. 133(Pt 6). P. 1747−54.
23. Bolles R.C. Avoidance and escape learning: simultaneous acquisition of different responses// J Comp Physiol Psychol. 1969. V. 68(3). P. 355−8.
24. Bonini N.M., Giasson B.I. Snaring the function of alpha-synuclein// Cell. 2005. V. 123(3). P. 359−61.
25. Bonsch D., Greifenberg V., Bayerlein K., Biermann T., Reulbach U., Hillemacher T., Kornhuber J., Bleich S. Alpha-synuclein protein levels are increased in alcoholic patients and are linked to craving// Alcohol Clin Exp
26. Res. 2005. V. 29(5). P. 763−5.
27. Bonsch D., Lederer T., Reulbach U., Hothorn T., Kornhuber J., Bleich S. Joint analysis of the NACP-REP1 marker within the alpha synuclein gene concludes association with alcohol dependence// Hum Mol Genet. 2005. V. 14(7). P. 967−71.
28. Bourin M., Hascoet M. The mouse light/dark box test// Eur J Pharmacol. 2003. V. 463(1−3). P. 55−65.
29. Boyer F., Balado E., Piazza P.V., Dreyer J.L., Deroche-Gamonet V. A decrease in gamma-synuclein expression within the nucleus accumbens increases cocaine intravenous self-administration in the rat// Addict Biol. 2011. V. 16(1). P. 120−3.
30. Boyer F., Dreyer J.L. Alpha-synuclein in the nucleus accumbens induces changes in cocaine behaviour in rats// Eur J Neurosci. 2007. V. 26(10). P. 2764−76.
31. Boyer F., Dreyer J.L. The role of gamma-synuclein in cocaine-induced behaviour in rats//Eur J Neurosci. 2008. V. 27(11). P. 2938−51.
32. Brenz Verca M.S., Bahi A., Boyer F., Wagner G.C., Dreyer J.L. Distribution of alpha- and gamma-synucleins in the adult rat brain and their modification by high-dose cocaine treatment// Eur J Neurosci. 2003. V. 18(7). P. 1923−38.
33. Briley M. Biochemical strategies in the search for cognition enhancers// Pharmacopsychiatry. 1990. V. 23 Suppl 2. P. 75−80.
34. Buccafusco J.J. Methods of behavior analysis in neuroscience. Boca Raton — London: CRC Press, 2001. 329 p.
35. Buchman V.L., Adu J., Pinon L.G., Ninkina N.N., Davies A.M. Persyn, a member of the synuclein family, influences neurofilament network integrity//Nat Neurosci. 1998. V. 1(2). P. 101−3.
36. Burre J., Sharma M., Tsetsenis T., Buchman V., Etherton M.R., Sudhof T.C. Alpha-synuclein promotes SNARE-eomplex assembly in vivo and in vitro// Science. 2010. V. 329(5999). P. 1663−7.
37. Castellano M.A., Diaz-Palarea M.D., Rodriguez M., Barroso J. Lateralization in male rats and dopaminergic system: evidence of right-side population bias// Physiol Behav. 1987. V. 40(5). P. 607−12.
38. Chandra S., Chen X., Rizo J., Jahn R., Sudhof T.C. A broken alpha -helix in folded alpha -Synuclein// J Biol Chem. 2003. V. 278(17). P. 15 313−8.
39. Chandra S., Gallardo G., Fernandez-Chacon R., Schluter O.M., Sudhof T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration// Cell. 2005. V. 123(3). P. 383−96.
40. Chen P.E., Specht C.G., Morris R.G., Schoepfer R. Spatial learning is unimpaired in mice containing a deletion of the alpha-synuclein locus// Eur J Neurosci. 2002. V. 16(1). P. 154−8.
41. Chen X., de Silva H.A., Pettenati M.J., Rao P.N., St George-Hyslop P., Roses A.D., Xia Y., Horsburgh K., Ueda K., Saitoh T. The human NACP/alpha-synuclein gene: chromosome assignment to 4q21.3-q22 and
42. TaqI RFLP analysis// Genomics. 1995. V. 26(2). P. 425−7.
43. Cheng F., Vivacqua G., Yu S. The role of alpha-synuclein in neurotransmission and synaptic plasticity// J Chem Neuroanat. 2011. V. 42(4). P. 242−8.
44. Choi J. S, Cain C. K, LeDoux J.E. The role of amygdala nuclei in the expression of auditory signaled two-way active avoidance in rats// Learn Mem. 2010. V. 17(3). P. 139−47.
45. Chu Y, Kordower J.H. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson’s disease?// Neurobiol Dis. 2007. V. 25(1). P. 134−49.
46. Clayton D. F, George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease// Trends Neurosci. 1998. V. 21(6). P. 249−54.
47. Cole R. N, Hart G.W. Cytosolic O-glycosylation is abundant in nerve terminals// J Neurochem. 2001. V. 79(5). P. 1080−9.
48. Colton C. A, Xu Q, Burke J. R, Bae S. Y, Wakefield J. K, Nair A, Strittmatter W. J, Vitek M.P. Disrupted spermine homeostasis: a novel mechanism in polyglutamine-mediated aggregation and cell death// J Neurosci. 2004. V. 24(32). P. 7118−27.
49. Dalfo E., Ferrer I. Alpha-synuclein binding to rab3a in multiple system atrophy//Neurosci Lett. 2005. V. 380(1−2). P. 170−5.
50. Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes// J Biol Chem. 1998. V. 273(16). P. 9443−9.
51. Davies P., Wang X., Sarell C.J., Drewett A., Marken F., Viles J.H., Brown
52. Deak F., Shin O.H., Tang J., Hanson P., Ubach J., Jahn R., Rizo J., Kavalali
53. E.T., Sudhof T.C. Rabphilin regulates SNARE-dependent re-priming of synaptic vesicles for fusion// EMBO J. 2006. V. 25(12). P. 2856−66.
54. Degroot A., Treit D. Dorsal and ventral hippocampal cholinergic systems modulate anxiety in the plus-maze and shock-probe tests// Brain Res. 2002. V. 949(1−2). P. 60−70.
55. Dorval V., Fraser P.E. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein// J Biol Chem. 2006. V. 281(15). P. 9919−24.
56. Duda J.E., Shah U., Arnold S.E., Lee V.M., Trojanowski J.Q. The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases// Exp Neurol. 1999. V. 160(2). P. 515−22.
57. Dunkley PR., Bobrovskaya L., Graham M.E., von Nagy-Felsobuki E.I., Dickson PW. Tyrosine hydroxylase phosphorylation: regulation and consequences// J Neurochem. 2004. V. 91(5). P. 1025−43.
58. Dursteler-Macfarland K.M., Brugger I., Bonsch D., Schmid O., Kornhuber J., Bleich S., Wiesbeck G.A. Alpha-synuclein and heroin craving in opiate-dependent patients on injectable heroin maintenance// Addiction biology. 2011.
59. Elrod K., Buccafusco J.J. An evaluation of the mechanism of scopolamine-induced impairment in two passive avoidance protocols// Pharmacol BiochemBehav. 1988. V. 29(1). P. 15−21.
60. Faure J.J., Hattingh S.M., Stein D.J., Daniels W.M. Proteomic analysisreveals differentially expressed proteins in the rat frontal cortex after133methamphetamine treatment// Metab Brain Dis. 2009. V. 24(4). P. 685−700.
61. Feany M.B., Bender W.W. A Drosophila model of Parkinson’s disease// Nature. 2000. V. 404(6776). P. 394−8.
62. File S.E., Kenny P.J., Cheeta S. The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety// Pharmacol Biochem Behav. 2000. V. 66(1). P. 65−72.
63. Fox M.A., Andrews A.M., Wendland J.R., Lesch K.P., Holmes A., Murphy D.L. A pharmacological analysis of mice with a targeted disruption of the serotonin transporter// Psychopharmacology (Berl). 2007. V. 195(2). P. 14 766.
64. Fujita M., Sugama S., Sekiyama K., Sekigawa A., Tsukui T., Nakai M., Waragai M., Takenouchi T., Takamatsu Y., Wei J., Rockenstein E., Laspada
65. A.R., Masliah E., Inoue S., Hashimoto M. A beta-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain// Nat Commun. 2010. V. 1. P. 110.
66. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions// Nat Cell Biol. 2002. V. 4(2). P. 160−4.
67. Fuss J., Ben Abdallah N.M., Hensley F.W., Weber K.J., Hellweg R., Gass P. Deletion of running-induced hippocampal neurogenesis by irradiation prevents development of an anxious phenotype in mice// PLoS One. 2010. V. 5(9).
68. Galvin J.E., Giasson B., Hurtig H.I., Lee V.M., Trojanowski J.Q. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology// Am J Pathol. 2000. V. 157(2). P. 361−8.
69. Galvin J.E., Schuck T.M., Lee V.M., Trojanowski J.Q. Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra// Exp Neurol. 2001. V. 168(2). P. 347−55.
70. George J.M., Jin H., Woods W.S., Clayton D.F. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch//Neuron. 1995. V. 15(2). P. 361−72.
71. Getova D.P., Doncheva N.D. Effects of ketamine on memory and nociception in rats// Folia Med (Plovdiv). 2011. V. 53(1). P. 53−9.
72. Giasson B.I., Forman M.S., Higuchi M., Golbe L.I., Graves C.L., Kotzbauer P.T., Trojanowski J.Q., Lee V.M. Initiation and synergistic fibrillization of tau and alpha-synuclein// Science. 2003. V. 300(5619). P. 636−40.
73. Giasson B.I., Lee V.M., Trojanowski J.Q. Interactions of amyloidogenic proteins// Neuromolecular Med. 2003. V. 4(1−2). P. 49−58.
74. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter// Nature. 1996. V. 379(6566). P. 606−12.
75. Glaser C.B., Yamin G., Uversky V.N., Fink A.L. Methionine oxidation, alpha-synuclein and Parkinson’s disease// Biochim Biophys Acta. 2005. V. 1703(2). P. 157−69.
76. Goldberg M.S., Lansbury P.T., Jr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson’s disease?// Nat Cell Biol. 2000. V. 2(7). P. El 15−9.
77. Golts N., Snyder H., Frasier M., Theisler C., Choi P., Wolozin B. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein// J Biol Chem. 2002. V. 277(18). P. 16 116−23.
78. Gosavi N., Lee H.J., Lee J.S., Patel S., Lee S.J. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion// J Biol Chem. 2002. V. 277(50). P. 48 984−92.
79. Graham D.R., Sidhu A. Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior// J Neurosci Res. 2010. V. 88(8). P. 1777−83.
80. Green R.J., Stanton M.E. Differential ontogeny of working memory and reference memory in the rat// Behav Neurosci. 1989. V. 103(1). P. 98−105.
81. Griffiths P.D., Dobson B.R., Jones G.R., Clarke D.T. Iron in the basal ganglia in Parkinson’s disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy// Brain. 1999. V. 122 (Pt 4). P. 667−73.
82. Guo J. T, Chen A. Q, Kong Q, Zhu H, Ma CM, Qin C. Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells// Cell Mol Neurobiol. 2008. V. 28(1). P. 35−47.
83. Gureviciene I, Gurevicius K, Tanila H. Role of alpha-synuclein in synaptic glutamate release//Neurobiol Dis. 2007. V. 28(1). P. 83−9.
84. Gureviciene I, Gurevicius K, Tanila H. Aging and alpha-synuclein affect synaptic plasticity in the dentate gyrus// J Neural Transm. 2009. V. 116(1). P. 13−22.
85. Hamilton D. A, Rosenfelt C. S, Whishaw I.Q. Sequential control of navigation by locale and taxon cues in the Morris water task// Behav Brain Res. 2004. V. 154(2). P. 385−97.
86. Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee V. M, Trojanowski J. Q, Mann D, Iwatsubo T. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions// J Biol Chem. 2002. V. 277(50). P. 49 071−6.
87. Hashimoto M, Hsu L. J, Sisk A, Xia Y, Takeda A, Sundsmo M, Masliah E. Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease// Brain Res. 1998. V. 799(2). P. 301−6.
88. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an antiparkinsonian factor//Neuron. 2001. V. 32(2). P. 213−23.
89. Haycock J.W. Phosphorylation of tyrosine hydroxylase in situ at serine 8, 19, 31, and 40// J Biol Chem. 1990. V. 265(20). P. 11 682−91.
90. Hebert C, Habimana A, Elie R, Reader T.A. Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: anautoradiographic study//Neurochem Int. 2001. V. 38(1). P. 63−74.
91. Hong J.G., Kim D.H., Park S .J., Kim J.M., Cai M., Liu X., Lee C.H., Ryu J.H. The memory-enhancing effects of Kami-ondam-tang in mice// J Ethnopharmacol. 2011. V. 137(1). P. 251−6.
92. Huang Z., Xu Z., Wu Y., Zhou Y. Determining nuclear localization of alpha-synuclein in mouse brains//Neuroscience. 2011. V. 199. P. 318−32.
93. Jakes R., Spillantini M.G., Goedert M. Identification of two distinct synucleins from human brain// FEBS Lett. 1994. V. 345(1). P. 27−32.
94. Jeannotte A.M., McCarthy J.G., Redei E.E., Sidhu A. Desipramine modulation of alpha-, gamma-synuclein, and the norepinephrine transporter in an animal model of depression// Neuropsychopharmacology. 2009. V. 34(4). P. 987−98.
95. Jeannotte A.M., Sidhu A. Regulation of the norepinephrine transporter by alpha-synuclein-mediated interactions with microtubules// Eur J Neurosci. 2007. V. 26(6). P. 1509−20.
96. Jeannotte A.M., Sidhu A. Regulated interactions of the norepineprhine transporter by the actin and microtubule cytoskeletons// J Neurochem. 2008. V. 105(5). P. 1668−82.
97. Jellinger K.A. A critical evaluation of current staging of alpha-synucleinpathology in Lewy body disorders// Biochim Biophys Acta. 2009. V. 1792(7). P. 730−40.
98. Jenco J.M., Rawlingson A., Daniels B., Morris A J. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins// Biochemistry. 1998. V. 37(14). P. 4901−9.
99. Jensen PH., Gai W.P. Alpha-synuclein. Axonal transport, ligand interaction and neurodegeneration//Adv Exp Med Biol. 2001. V. 487. P. 129−34.
100. Jensen PH., Islam K., Kenney J., Nielsen M.S., Power J., Gai W.P. Microtubule-associated protein IB is a component of cortical Lewy bodies and binds alpha-synuclein filaments// J Biol Chem. 2000. V. 275(28). P. 21 500−7.
101. Jensen P.J., Alter B.J., O’Malley K.L. Alpha-synuclein protects naive but not dbcAMP-treated dopaminergic cell types from l-methyl-4-phenylpyridinium toxicity// J Neurochem. 2003. V. 86(1). P. 196−209.
102. Jones S.R., Gainetdinov R.R., Wightman R.M., Caron M.G. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter// J Neurosci. 1998. V. 18(6). P. 1979−86.
103. Junn E., Mouradian M.M. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine// Neurosci Lett. 2002. V. 320(3). P. 146−50.
104. Kalueff A.V., Fox M.A., Gallagher P. S., Murphy D.L. Hypolocomotion, anxiety and serotonin syndrome-like behavior contribute to the complex phenotype of serotonin transporter knockout mice// Genes Brain Behav. 2007. V. 6(4). P. 389−400.
105. Katonai R.E., Szekely A., Sasvari-Szekely M. Effect of dopaminergic and serotonergic gene variants on cognitive performance.// Neuropsychopharmacol Hung. 2011. V. 13(2). P. 81−6.
106. Katzung B.G., Masters S.B., Trevor A.J. Basic & clinical pharmacology. New York London: McGraw-Hill Medical- McGraw-Hill distributor., 2009. 1218 p.
107. Kirmayer L.J., Lemelson R., Barad M. Understanding trauma: integrating biological, clinical, and cultural perspectives. Cambridge — New York: Cambridge University Press, 2007. xxviii, 519 p.
108. Klinkenberg I., Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies//Neurosci Biobehav Rev. 2010. V. 34(8). P. 1307−50.
109. Konig M., Zimmer A.M., Steiner H., Holmes P.V., Crawley J.N., Brownstein M.J., Zimmer A. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin//Nature. 1996. V. 383(6600). P. 535−8.
110. Kontopoulos E., Parvin J.D., Feany M.B. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity// Hum Mol Genet. 2006. V. 15(20). P. 3012−23.
111. Kramer M.L., Schulz-Schaeffer W.J. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies// J Neurosci. 2007. V. 27(6). P. 1405−10.
112. Kuwahara T., Tonegawa R., Ito G., Mitani S., Iwatsubo T. Phosphorylation of alpha-synuclein at Serl29 reduces neuronal dysfunction by lowering its membrane-binding property in Caenorhabditis elegans// J Biol Chem. 2012.
113. Larsson A., Wilhelmsson U., Pekna M., Pekny M. Increased cell proliferation and neurogenesis in the hippocampal dentate gyrus of old GFAP (-/-)Vim (-/-) mice//Neurochem Res. 2004. V. 29(11). P. 2069−73.
114. Lavedan C. The synuclein family// Genome Res. 1998. V. 8(9). P. 871−80.
115. Lavedan C., Leroy E., Dehejia A., Buchholtz S., Dutra A., Nussbaum R.L., Polymeropoulos M.H. Identification, localization and characterization of thehuman gamma-synuclein gene// Hum Genet. 1998. V. 103(1). P. 106−12.
116. Lee F.J., Liu F., Pristupa Z.B., Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis// FASEB J. 2001. V. 15(6). P. 916−26.
117. Li J., Uversky V.N., Fink A.L. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson’s disease point mutations A3 OP and A53T// Neurotoxicology. 2002. V. 23(4−5). P. 553−67.
118. Liang T., Carr L.G. Regulation of alpha-synuclein expression in alcohol-preferring and -non preferring rats// J Neurochem. 2006. V. 99(2). P. 470−82.
119. Lim Y., Kehm V.M., Lee E.B., Soper J.H., Li C., Trojanowski J.Q., Lee V.M. alpha-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies// J Neurosci. 2011. V. 31(27). P. 10 076−87.
120. Lin X.J., Zhang F., Xie Y.Y., Bao W.J., He J.H., Hu H.Y. Secondary structural formation of alpha-synuclein amyloids as revealed by g-factor of solid-state circular dichroism// Biopolymers. 2006. V. 83(3). P. 226−32.
121. Lindersson E., Beedholm R., Hojrup P., Moos T., Gai W., Hendil K.B., Jensen P.H. Proteasomal inhibition by alpha-synuclein filaments and oligomers// J Biol Chem. 2004. V. 279(13). P. 12 924−34.
122. Liu C., Fei E., Jia N., Wang H., Tao R., Iwata A., Nukina N., Zhou J., Wang G. Assembly of lysine 63-linked ubiquitin conjugates by phosphorylated alpha-synuclein implies Lewy body biogenesis// J Biol Chem. 2007. V. 282(19). P. 14 558−66.
123. Liu D., Jin L., Wang H., Zhao H., Zhao C., Duan C., Lu L., Wu B., Yu S., Chan P., Li Y., Yang H. Silencing alpha-synuclein gene expression enhancestyrosine hydroxylase activity in MN9D cells// Neurochem Res. 2008. V. 33(7). P. 1401−9.
124. Liu S, Ninan I, Antonova I, Battaglia F, Trinchese F, Narasanna A, Kolodilov N, Dauer W, Hawkins R. D, Arancio O. alpha-Synuclein produces a long-lasting increase in neurotransmitter release// EMBO J. 2004. V. 23(22). P. 4506−16.
125. Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon H. K, Brundin P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line// J Biol Chem. 2002. V. 277(41). P. 38 884−94.
126. Lotharius J, Brundin P. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson’s disease// Hum Mol Genet. 2002. V. 11(20). P. 2395−407.
127. Lykkebo S, Jensen P.H. Alpha-synuclein and presynaptic function: implications for Parkinson’s disease// Neuromolecular Med. 2002. V. 2(2). P. 115−29.
128. Malleret G, Hen R, Guillou J. L, Segu L, Buhot M.C. 5-HT1B receptor knock-out mice exhibit increased exploratory activity and enhanced spatial memory performance in the Morris water maze// J Neurosci. 1999. V. 19(14). P. 6157−68.
129. Maroteaux L, Campanelli J. T, Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal// J Neurosci. 1988. V. 8(8). P. 2804−15.
130. Marques J. M, Olsson I. A, Ogren S. O, Dahlborn K. Evaluation of exploration and risk assessment in pre-weaning mice using the novel cagetest// Physiol Behav. 2008. V. 93(1−2). P. 139−47.
131. Martin L.J., Pan Y., Price A.C., Sterling W., Copeland N.G., Jenkins N.A., Price D.L., Lee M.K. Parkinson’s disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death// J Neurosci. 2006. V. 26(1). P. 41−50.
132. Mash D.C., Adi N., Duque L., Pablo J., Kumar M., Ervin F.R. Alpha synuclein protein levels are increased in serum from recently abstinent cocaine abusers// Drug Alcohol Depend. 2008. V. 94(1−3). P. 246−50.
133. Mash D.C., Ouyang Q., Pablo J., Basile M., Izenwasser S., Lieberman A., Perrin R.J. Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons// J Neurosci. 2003. V. 23(7). P. 2564−71.
134. Mash D.C., Pablo J., Ouyang Q., Hearn W.L., Izenwasser S. Dopamine transport function is elevated in cocaine users// J Neurochem. 2002. V. 81(2). P. 292−300.
135. Mazzulli J.R., Armakola M., Dumoulin M., Parastatidis I., Ischiropoulos H. Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence// J Biol Chem. 2007. V. 282(43). P. 31 621−30.
136. McNamara R.K., Skelton R.W. The neuropharmacological and neurochemical basis of place learning in the Morris water maze// Brain Res Brain Res Rev. 1993. V. 18(1). P. 33−49.
137. Mezey E., Dehejia A., Harta G., Papp M.I., Polymeropoulos M.H.,
138. Brownstein M.J. Alpha synuclein in neurodegenerative disorders: murderer or accomplice?// Nat Med. 1998. V. 4(7). P. 755−7.
139. Molodtsova G.F. Metabolism and receptor binding of serotonin in brain structures during performance of a conditioned passive avoidance response// Neurosci Behav Physiol. 2005. V. 35(7). P. 685−92.
140. Monti B., Polazzi E., Batti L., Crochemore C., Virgili M., Contestabile A. Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death// J Neurochem. 2007. V. 103(2). P. 518−30.
141. Murphy D.D., Rueter S.M., Trojanowski J.Q., Lee V.M. Synucleins are developmental^ expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons// J Neurosci. 2000. V. 20(9). P. 3214−20.
142. Nakajo S., Tsukada K., Omata K., Nakamura Y., Nakaya K. A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation// Eur J Biochem. 1993. V. 217(3). P. 1057−63.
143. Nakamura T., Yamashita H., Nagano Y., Takahashi T., Avraham S., Avraham H., Matsumoto M., Nakamura S. Activation of Pyk2/RAFTK induces tyrosine phosphorylation of alpha-synuclein via Src-family kinases// FEBS Lett. 2002. V. 521(1−3). P. 190−4.
144. Nielsen M.S., Vorum H., Lindersson E., Jensen PH. Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization// J Biol Chem. 2001. V. 276(25). P. 22 680−4.
145. Ninkina N.N., Alimova-Kost M.V., Paterson J.W., Delaney L., Cohen B.B., Imreh S., Gnuchev N.V., Davies A.M., Buchman V.L. Organization, expression and polymorphism of the human persyn gene// Hum Mol Genet. 1998. V. 7(9). P. 1417−24.
146. Nonaka T., Iwatsubo T., Hasegawa M. Ubiquitination of alpha-synuclein// Biochemistry. 2005. V. 44(1). P. 361−8.
147. Norris E.H., Giasson B.I., Lee V.M. Alpha-synuclein: normal function and role in neurodegenerative diseases// Curr Top Dev Biol. 2004. V. 60. P. 1754.
148. Oaks A.W., Sidhu A. Synuclein modulation of monoamine transporters// FEBS Lett. 2011. V. 585(7). P. 1001−6.
149. Oksman M., Tanila H., Yavich L. Brain reward in the absence of alpha-synuclein//Neuroreport. 2006. V. 17(11). P. 1191−4.
150. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J., Wolozin B. alpha-Synuclein shares physical and functional homology with 14−3-3 proteins//J Neurosci. 1999. V. 19(14). P. 5782−91.
151. Outeiro T.F., Klucken J., Strathearn K.E., Liu F., Nguyen P., Rochet J.C., Hyman B.T., McLean P.J. Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation// Biochem Biophys Res Commun. 2006. V. 351(3). P. 631−8.
152. Parent M.B., Baxter M.G. Septohippocampal acetylcholine: involved in but not necessary for learning and memory?// Learn Mem. 2004. V. 11(1). P. 920.
153. Park S.M., Jung H.Y., Kim T.D., Park J.H., Yang C.H., Kim J. Distinct rolesof the N-terminal-binding domain and the C-terminal-solubilizing domain of alpha-synuclein, a molecular chaperone// J Biol Chem. 2002. V. 277(32). P. 28 512−20.
154. Pelkonen A., Yavich L. Neuromuscular pathology in mice lacking alpha-synuclein// Neurosci Lett. 2011. V. 487(3). P. 350−3.
155. Pena-Oliver Y., Buchman V.L., Stephens D.N. Lack of involvement of alpha-synuclein in unconditioned anxiety in mice// Behav Brain Res. 2010. V. 209(2). P. 234−40.
156. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis// J Neurosci. 2002. V. 22(8). P. 3090−9.
157. Perry E., Walker M., Grace J., Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness?// Trends Neurosci. 1999. V. 22(6). P. 273−80.
158. Phillips P.E., Stuber G.D., Heien M.L., Wightman R.M., Carelli R.M. Subsecond dopamine release promotes cocaine seeking// Nature. 2003. V. 422(6932). P. 614−8.
159. Ponka P., Beaumont C., Richardson D.R. Function and regulation of transferrin and ferritin// Semin Hematol. 1998. V. 35(1). P. 35−54.
160. Pronin A.N., Morris A.J., Surguchov A., Benovic J.L. Synucleins are a novel class of substrates for G protein-coupled receptor kinases// J Biol Chem. 2000. V. 275(34). P. 26 515−22.
161. Ramirez-Amaya V., Balderas I., Sandoval J., Escobar M.L., Bermudez-Rattoni F. Spatial long-term memory is related to mossy fiber synaptogenesis// JNeurosci. 2001. V. 21(18). P. 7340−8.
162. Ramos A., Mormede P. Stress and emotionality: a multidimensional and genetic approach//Neurosci Biobehav Rev. 1998. V. 22(1). P. 33−57.
163. Recchia A., Debetto P., Negro A., Guidolin D., Skaper S.D., Giusti P. Alpha-synuclein and Parkinson’s disease// FASEB J. 2004. V. 18(6). P. 617−26.
164. Redish A.D. Beyond the cognitive map: from place cells to episodic memory. Cambridge, Mass.- London: MIT Press, 1999. xviii, 420 p.
165. Roodveldt C., Bertoncini C.W., Andersson A., van der Goot A.T., Hsu S.T.,
166. Fernandez-Montesinos R., de Jong J., van Ham T.J., Nollen E.A., Pozo D.,
167. Christodoulou J., Dobson C.M. Chaperone proteostasis in Parkinson’sdisease: stabilization of the Hsp70/alpha-synuclein complex by Hip// EMBO148
168. J. 2009. V. 28(23). P. 3758−70.
169. Ruff H. A, Saltarelli L.M. Exploratory play with objects: basic cognitive processes and individual differences// New Dir Child Dev. 1993. (59). P. 516.
170. Sampathu D. M, Giasson B. I, Pawlyk A. C, Trojanowski J. Q, Lee V.M. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies// Am J Pathol. 2003. V. 163(1). P. 91−100.
171. Schneider B. L, Seehus C. R, Capowski E. E, Aebischer P, Zhang S. C, Svendsen C.N. Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation// Hum Mol Genet. 2007. V. 16(6). P. 651−66.
172. Self D. W, McClenahan A. W, Beitner-Johnson D, Terwilliger R. Z, Nestler E.J. Biochemical adaptations in the mesolimbic dopamine system in response to heroin self-administration// Synapse. 1995. V. 21(4). P. 312−8.
173. Shamoto-Nagai M, Maruyama W, Hashizume Y, Yoshida M, Osawa T,
174. Sharp T., Zetterstrom T., Ljungberg T., Ungerstedt U. Effect of sulpiride on amphetamine-induced behaviour in relation to changes in striatal dopamine release in vivo// Eur J Pharmacol. 1986. V. 129(3). P. 411−5.
175. Shepherd J.K., Grewal S.S., Fletcher A., Bill D.J., Dourish C.T. Behavioural and pharmacological characterisation of the elevated «zero-maze» as an animal model of anxiety// Psychopharmacology (Berl). 1994. V. 116(1). P. 56−64.
176. Shibayama-Imazu T., Ogane K., Hasegawa Y., Nakajo S., Shioda S., Ochiai H., Nakai Y., Nakaya K. Distribution of PNP 14 (beta-synuclein) in neuroendocrine tissues: localization in Sertoli cells// Mol Reprod Dev. 1998. V. 50(2). P. 163−9.
177. Sidhu A., Wersinger C., Moussa C.E., Vernier P. The role of alpha-synuclein in both neuroprotection and neurodegeneration// Ann N Y Acad Sci. 2004. V. 1035. P. 250−70.
178. Sidhu A., Wersinger C., Vernier P. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson’s disease// FEBS Lett. 2004. V. 565(1−3). P. 1−5.
179. Sidhu A., Wersinger C., Vernier P. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?// FASEB J. 2004. V.18(6). P. 637−47.
180. Song D.D., Shults C.W., Sisk A., Rockenstein E., Masliah E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP// Exp Neurol. 2004. V. 186(2). P. 158−72.
181. Sotnikova T.D., Beaulieu J.M., Barak L.S., Wetsel W.C., Caron M.G., Gainetdinov R.R. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease// PLoS Biol. 2005. V. 3(8). P. e271.
182. Souza J.M., Giasson B.I., Lee V.M., Ischiropoulos H. Chaperone-like activity of synucleins// FEBS Lett. 2000. V. 474(1). P. 116−9.
183. Specht C.G., Schoepfer R. Deletion of multimerin-1 in alpha-synuclein-deficient mice// Genomics. 2004. V. 83(6). P. 1176−8.
184. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. alpha-Synuelein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies// Proc Natl Acad Sci USA. 1998. V. 95(11). P. 6469−73.
185. Spillantini M.G., Divane A., Goedert M. Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35// Genomics. 1995. V. 27(2). P. 379−81.
186. Spillantini M.G., Goedert M. The alpha-synucleinopathies: Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy// Ann N Y Acad Sci. 2000. V. 920. P. 16−27.
187. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies// Nature. 1997. V. 388(6645). P. 839−40.
188. Strekalova T., Spanagel R., Bartsch D., Henn F.A., Gass P. Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration//Neuropsychopharmacology. 2004. V. 29(11). P. 2007−17.
189. Sudhof T.C., Rizo J. Synaptic Vesicle Exocytosis// Cold Spring Harb Perspect Biol. 2011.
190. Sunderland T., Tariot P.N., Newhouse PA. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatrie populations// Brain Res. 1988. V. 472(4). P. 371−89.
191. Surgucheva I., McMahon B., Surguchov A. gamma-synuclein has a dynamic intracellular localization// Cell Motil Cytoskeleton. 2006. V. 63(8). P. 44 758.
192. Surgucheva I., Ninkina N., Buchman V.L., Grasing K., Surguchov A. Protein aggregation in retinal cells and approaches to cell protection// Cell Mol Neurobiol. 2005. V. 25(6). P. 1051−66.
193. Surguchov A. Molecular and cellular biology of synucleins// Int Rev Cell Mol Biol. 2008. V. 270. P. 225−317.
194. Szargel R., Rott R, Engelender S. Synphilin-1 isoforms in Parkinson’s152disease: regulation by phosphorylation and ubiquitylation// Cell Mol Life Sci. 2008. V. 65(1). P. 80−8.
195. Takahashi M., Ko L.W., Kulathingal J., Jiang P., Sevlever D., Yen S.H. Oxidative stress-induced phosphorylation, degradation and aggregation of alpha-synuclein are linked to upregulated CK2 and cathepsin D// Eur J Neurosci. 2007. V. 26(4). P. 863−74.
196. Takeda A., Mallory M., Sundsmo M., Honer W., Hansen L., Masliah E. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders//Am J Pathol. 1998. V. 152(2). P. 367−72.
197. Telensky P., Svoboda J., Blahna K., Bures J., Kubik S., Stuchlik A. Functional inactivation of the rat hippocampus disrupts avoidance of a moving object// Proc Natl Acad Sci U S A. 2011. V. 108(13). P. 5414−8.
198. Tofaris G.K., Razzaq A., Ghetti B., Lilley K.S., Spillantini M.G. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function// J Biol Chem. 2003. V. 278(45). P. 44 405−11.
199. Torres G.E., Gainetdinov R.R., Caron M.G. Plasma membrane monoamine transporters: structure, regulation and function// Nat Rev Neurosci. 2003. V. 4(1). P. 13−25.
200. Tyler T.D., Tessel R.E. Amphetamine’s locomotor-stimulant and noreprinephrine-releasing effects: evidence for selective antagonism by nisoxetine// Psychopharmacology (Berl). 1979. V. 64(3). P. 291−6.
201. Ulmer T.S., Bax A., Cole N.B., Nussbaum R.L. Structure and dynamics of micelle-bound human alpha-synuclein// J Biol Chem. 2005. V. 280(10). P. 9595−603.
202. Uversky V.N., Fink A.L. Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle// FEBS Lett. 2002. V. 522(1−3). P. 9−13.
203. Uversky V.N., Li J., Fink A.L. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson’s disease// FEBS Lett. 2001. V. 500(3). P. 105−8.
204. Varanese S., Perfetti B., Ghilardi M.F., Di Rocco A. Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson’s disease// PLoS One. 2011. V. 6(3). P. el7846.
205. Vazquez J., Baghdoyan H.A. GABAA receptors inhibit acetylcholine release in cat pontine reticular formation: implications for REM sleep regulation// J Neurophysiol. 2004. V. 92(4). P. 2198−206.
206. Verheij M.M., Cools A.R. Twenty years of dopamine research: individual differences in the response of accumbal dopamine to environmental and pharmacological challenges// Eur J Pharmacol. 2008. V. 585(2−3). P. 228−44.
207. Wadsworth J.D., Hill A.F., Joiner S., Jackson G.S., Clarke A.R., Collinge J. Strain-specific prion-protein conformation determined by metal ions// Nat Cell Biol. 1999. V. 1(1). P. 55−9.
208. Walker D.L., Davis M. Anxiogenic effects of high illumination levels assessed with the acoustic startle response in rats// Biol Psychiatry. 1997. V. 42(6). P. 461−71.
209. Walker S.J., Grant K.A. Peripheral blood alpha-synuclein mRNA levels areelevated in cynomolgus monkeys that chronically self-administer ethanol// Alcohol. 2006. V. 38(1). P. 1−4.
210. Watson J. B, Hatami A, David H, Masliah E, Roberts K, Evans C. E, Levine M.S. Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein// Neuroscience. 2009. V. 159(2). P. 501−13.
211. Waxman E. A, Giasson B.I. Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau// JNeurosci. 2011. V. 31(21). P. 7604−18.
212. Weihmuller F. B, O’Dell S. J, Marshall J.F. MK-801 protection against methamphetamine-induced striatal dopamine terminal injury is associated with attenuated dopamine overflow// Synapse. 1992. V. 11(2). P. 155−63.
213. Weinreb P. H, Zhen W, Poon A. W, Conway K. A, Lansbury P. T, Jr. NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded//Biochemistry. 1996. V. 35(43). P. 13 709−15.
214. Wersinger C, Jeannotte A, Sidhu A. Attenuation of the norepinephrine transporter activity and trafficking via interactions with alpha-synuclein// Eur JNeurosci. 2006. V. 24(11). P. 3141−52.
215. Wersinger C, Prou D, Vernier P, Sidhu A. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress// FASEB J. 2003. V. 17(14). P. 2151−3.
216. Wersinger C, Rusnak M, Sidhu A. Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein// Eur J Neurosci. 2006. V. 24(1). P. 55−64.
217. Wersinger C, Sidhu A. Attenuation of dopamine transporter activity byalpha-synuclein// Neurosci Lett. 2003. V. 340(3). P. 189−92.
218. Wersinger C., Sidhu A. Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter// Biochemistry. 2005. V. 44(41). P. 13 612−24.
219. Wersinger C., Sidhu A. Partial regulation of serotonin transporter function by gamma-synuclein// Neurosci Lett. 2009. V. 453(3). P. 157−61.
220. Withers G.S., George J.M., Banker G.A., Clayton D.F. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons// Brain Res Dev Brain Res. 1997. V. 99(1). P. 87−94.
221. Wood S.J., Wypych J., Steavenson S., Louis J.C., Citron M., Biere A.L. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson’s disease// J Biol Chem. 1999. V. 274(28). P. 19 509−12.
222. Wu B., Liu Q., Duan C., Li Y., Yu S., Chan P., Ueda K., Yang H. Phosphorylation of alpha-synuclein upregulates tyrosine hydroxylase activity in MN9D cells//Acta Histochem. 2011. V. 113(1). P. 32−5.
223. Wu Y., Matsui H., Tomizawa K. Amphiphysin I and regulation of synaptic vesicle endocytosis//Acta Med Okayama. 2009. V. 63(6). P. 305−23.
224. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease// Nat Med. 2002. V. 8(6). P. 600−6.
225. Xu S., Zhou M., Yu S., Cai Y., Zhang A., Ueda K., Chan P. Oxidative stress induces nuclear translocation of C-terminus of alpha-synuclein in dopaminergic cells// Biochem Biophys Res Commun. 2006. V. 342(1). P. 330−5.
226. Yavich L., Jakala P., Tanila H. Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha-synuclein knockout and A3 OP transgenic mice// J Neurochem. 2006. V. 99(3). P. 724−32.
227. Yavich L., Tanila H., Vepsalainen S., Jakala P. Role of alpha-synuclein in presynaptic dopamine recruitment// J Neurosci. 2004. V. 24(49). P. 1 116 570.
228. Yu S., Zuo X., Li Y., Zhang C., Zhou M., Zhang Y.A., Ueda K., Chan P. Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells// Neurosci Lett. 2004. V. 367(1). P. 34−9.
229. Zhang H., Kouadio A., Cartledge D., Godwin A.K. Role of gamma-synuclein in microtubule regulation// Exp Cell Res. 2011. V. 317(10). P. 1330−9.
230. Zhong S.C., Luo X., Chen X.S., Cai Q.Y., Liu J., Chen X.H., Yao Z.X. Expression and subcellular location of alpha-synuclein during mouse-embryonic development// Cell Mol Neurobiol. 2010. V. 30(3). P. 469−82.
231. Zhou Y., Inaba S., Liu J. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment// Int J Oncol. 2006. V. 29(1). P. 289−95.
232. Zhu Y., Duan C., Lu L., Gao H., Zhao C., Yu S., Ueda K., Chan P., Yang H. alpha-Synuclein overexpression impairs mitochondrial function by associating with adenylate translocator// Int J Biochem Cell Biol. 2011. V. 43(5). P. 732−41.
233. Zielinski P., Cotton M.M. Pavlovian trace conditioning and inhibition of fear in shuttlebox-avoidance behavior// Psychol Rep. 1982. V. 51(1). P. 267−71.